Abeona Therapeutics Reports Q3 2026 Revenue Growth and Improved Net Loss
Abeona Therapeutics (ABEO) reported third-quarter 2026 net revenue of $13.5 million, an 18% increase from the previous quarter, driven by increased activity with its ZEVASKYN treatment. The company significantly narrowed its net loss to $4.8 million ($0.08 per share), a substantial improvement from the $20.2 million loss reported in Q2. Total patients treated with ZEVASKYN reached 15, supported by an expanding network of eight Qualified Treatment Centers. The company is also advancing its pipeline through the acquisition of ABO-801 from Ellodi Pharmaceuticals via a stock-based deal. Management highlighted the significant market potential for ABO-801 in treating Eosinophilic Esophagitis (EoE), estimating peak annual sales could exceed $750 million. To support ongoing commercialization and development, Abeona announced a $30 million private placement.
Tickers: $ABEO
Topics: Manufacturing Performance Net Loss Net Revenue ZEVASKYN treatment